ArticlePediatric research2026
Intravitreal Bevacizumab nanoparticles ameliorates retinal vasculopathy in an in vivo mouse model of retinopathy of prematurity.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNanoparticles enable sustained drug release. Infants with retinopathy of prematurity (ROP) treated with Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, develop systemic toxicity due to repeat dosing from a short half-life. We optimized fabrication of Bevacizumab nanoparticles in a mouse oxygen-induced retinopathy (OIR) model.
methodsBevacizumab nanoparticle fabrication was optimized for polymer type and ratio, solvent, drug loading capacity (DL) %, and encapsulation efficiency (EE) %. Nanoparticles were characterized using Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), and Fourier-transform infrared spectroscopy (FTIR). C57BL6/J mice exposed to OIR received intravitreal Empty (n = 18), Bevacizumab-loaded nanoparticles (n = 18), or Free Bevacizumab (n = 12) at P13 to right eyes. Fluorescein Angiography (FA) was performed at P20. Retinal avascular area, arterial tortuosity, and vein width were quantified.
resultsSEM showed spherical nanospheres. TEM and FTIR confirmed drugs within nanospheres. DL and EE were optimized at 2.3% and 80%. There was sustained drug release of 80% at 72 h. FA showed increased retinal avascular area, reduced retinal artery tortuosity, and retinal vein width in Bevacizumab nanoparticle treated right eyes.
conclusionsIntravitreal administration of Bevacizumab-loaded nanoparticles significantly improved retinal vasculopathy in mice with OIR, without repeat dosing. Further toxicity studies are needed before clinical translation. IMPACT: Retinopathy of Prematurity is treated with anti-vascular endothelial growth factor drugs such as Bevacizumab. Anti-VEGF drugs result in systemic toxicity from repeat dosing due to their short half-life. We, for the first time, show the feasibility and optimization of nanoparticle formulation of bevacizumab in a mouse model of ROP. Intravitreal Bevacizumab nanoparticles may prevent systemic toxicity and improve outcomes in infants with ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.